{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:59:05Z","timestamp":1772265545080,"version":"3.50.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jconrel.2023.10.050","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T07:28:02Z","timestamp":1700119682000},"page":"654-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system"],"prefix":"10.1016","volume":"364","author":[{"given":"Philipp","family":"Reus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Guthmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd","family":"Agbaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Issmail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Eberlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam M.","family":"Nordling-David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doaa","family":"Jbara-Agbaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denisa","family":"Bojkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Burger-Kentischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Zaliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Gribbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimo","family":"Kannt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gershon","family":"Golomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.10.050_bb0025","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","article-title":"Therapeutic monoclonal antibodies for covid-19 management: an update","volume":"22","author":"Chavda","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109075","article-title":"Current evidence on the use of anakinra in covid-19","volume":"111","author":"Khani","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0035","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0040","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0045","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.apsb.2021.03.028","article-title":"Can remdesivir and its parent nucleoside gs-441524 be potential oral drugs? An in vitro and in vivo dmpk assessment","volume":"11","author":"Xie","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a sars-cov-2 replication inhibitor","volume":"60","author":"Humeniuk","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0055","series-title":"Infectious Diseases (Except HIV\/AIDS)","article-title":"The paxlovid rebound study: a prospective cohort study to evaluate viral and symptom rebound differences between paxlovid and untreated covid-19 participants","author":"Pandit","year":"2022"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0060","series-title":"Drug Repurposing \u2013 Hypothesis, Molecular Aspects and Therapeutic Applications","article-title":"Drug repurposing (dr): An emerging approach in drug discovery","author":"Rudrapal","year":"2020"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41597-021-00848-4","article-title":"A sars-cov-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection","volume":"8","author":"Ellinger","year":"2021","journal-title":"Sci. Data"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0070","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.gie.2008.10.046","article-title":"Nafamostat mesylate in the prevention of post-ercp pancreatitis and risk factors for post-ercp pancreatitis","volume":"69","author":"Choi","year":"2009","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPA.0b013e3181f94d46","article-title":"Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial","volume":"40","author":"Yoo","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","article-title":"Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies","volume":"109","author":"Minakata","year":"2019","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0085","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1248\/cpb.33.1458","article-title":"Synthesis and structure-activity study of protease inhibitors. Iv. Amidinonaphthols and related acyl derivatives","volume":"33","author":"Aoyama","year":"1985","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0090","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00216-008-2054-4","article-title":"A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and esi-ms detection: more accurate evaluation for pharmacokinetic study","volume":"391","author":"Cao","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0095","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002392","article-title":"Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial","volume":"94","author":"Choi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0100","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/molecules27061881","article-title":"Pharmacokinetics of nafamostat, a potent serine protease inhibitor, by a novel lc-ms\/ms analysis","volume":"27","author":"Oh","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103856","article-title":"Randomised controlled trial of intravenous nafamostat mesylate in covid pneumonitis: phase 1b\/2a experimental study to investigate safety, pharmacokinetics and pharmacodynamics","volume":"76","author":"Quinn","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0110","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of sars-cov-2: new treatment option for covid-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130094","article-title":"Identification of nafamostat and vr23 as covid-19 drug candidates by targeting 3clpro and plpro","volume":"1233","author":"Bhowmik","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits sars-cov-2 activation by tmprss2-related proteases and its metabolite gbpa exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101169","article-title":"Nafamostat in hospitalized patients with moderate to severe covid-19 pneumonia: a randomised phase ii clinical trial","volume":"41","author":"Zhuravel","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijid.2022.12.039","article-title":"Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with covid-19 pneumonia","volume":"128","author":"Ikeda","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1476-5381.1994.tb14040.x","article-title":"Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on na+ and k+ transport properties in the rabbit cortical collecting duct","volume":"111","author":"Muto","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0150","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1016\/j.bpj.2022.08.034","article-title":"Structural study of the upa-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat","volume":"121","author":"Zhou","year":"2022","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0155","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1248\/yakushi1947.105.5_512","article-title":"Stability studies on nafamstat mesilate in aqueous solution. I. Kinetic studies in various ph and temperature conditions, Yakugaku zasshi","volume":"105","author":"Arakawa","year":"1985","journal-title":"J. Pharm. Soc. Jpn."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00970-21","article-title":"The tmprss2 inhibitor nafamostat reduces sars-cov-2 pulmonary infection in mouse models of covid-19","volume":"12","author":"Li","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2019.11.006","article-title":"A randomized, double-blind, placebo-controlled phase 1b\/2 study of ralimetinib, a p38 mapk inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0170","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/MCB.19.4.2435","article-title":"Mitogen-activated protein kinases: specific messages from ubiquitous messengers","volume":"19","author":"Schaeffer","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 mapk signalling","volume":"429","author":"Cuadrado","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0180","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00705-021-04958-7","article-title":"The roles of signaling pathways in sars-cov-2 infection; lessons learned from sars-cov and mers-cov","volume":"166","author":"Hemmat","year":"2021","journal-title":"Arch. Virol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0185","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The global phosphorylation landscape of sars-cov-2 infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yjmcc.2020.05.007","article-title":"P38 mapk inhibition: a promising therapeutic approach for covid-19","volume":"144","author":"Grimes","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120809","article-title":"Recent clinical findings on the role of kinase inhibitors in covid-19 management","volume":"306","author":"Malekinejad","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0200","series-title":"Vitam. Horm.","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0083-6729(00)60022-5","article-title":"Liposome targeting to tumors using vitamin and growth factor receptors","author":"Drummond","year":"2000"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0205","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1080\/21691401.2017.1290647","article-title":"Liposome-targeted delivery for highly potent drugs","volume":"45","author":"Bardania","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0210","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1021\/acsabm.0c00705","article-title":"Recent advancements in liposome-targeting strategies for the treatment of gliomas: a systematic review","volume":"3","author":"Li","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil \u2014 the first fda-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jconrel.2023.05.010","article-title":"Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of sars-cov-2 caused covid-19 and other viral diseases","volume":"358","author":"Homaeigohar","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0230","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/a-1860-2610","article-title":"Covid-19 and lipid disorders","volume":"54","author":"Julius","year":"2022","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0235","doi-asserted-by":"crossref","first-page":"11860","DOI":"10.3390\/ijms241411860","article-title":"Low-density lipoprotein receptor (ldlr) is involved in internalization of lentiviral particles pseudotyped with sars-cov-2 spike protein in ocular cells","volume":"24","author":"Uppal","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1165\/rcmb.2016-0043TR","article-title":"Heparan sulfate in the developing, healthy, and injured lung","volume":"55","author":"Haeger","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0255","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"Sars-cov-2 infection depends on cellular heparan sulfate and ace2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0260","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41421-020-00222-5","article-title":"Heparan sulfate assists sars-cov-2 in cell entry and can be targeted by approved drugs in vitro","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.628551","article-title":"Elucidating the interactions between heparin\/heparan sulfate and sars-cov-2-related proteins\u2014an important strategy for developing novel therapeutics for the covid-19 pandemic","volume":"7","author":"Yu","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0270","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/cancers11040442","article-title":"Targeted siRNA nanoparticles for mammary carcinoma therapy","volume":"11","author":"Ben-David-Naim","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective\u2014a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0280","series-title":"Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases","first-page":"493","article-title":"Biologics and vaccines for nasal and pulmonary drug delivery","author":"Komalla","year":"2022"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0285","first-page":"L833","article-title":"Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia","volume":"282","author":"Southam","year":"2002","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0290","article-title":"Visualization of murine intranasal dosing efficiency using luminescent francisella tularensis: effect of instillation volume and form of anesthesia","volume":"7","author":"Miller","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0295","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"Pegylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo","volume":"32","author":"Semple","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0305","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1056\/NEJMc2001899","article-title":"Evidence of sars-cov-2 infection in returning travelers from Wuhan, China","volume":"382","author":"Hoehl","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1208\/s12248-008-9060-5","article-title":"Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization","volume":"10","author":"Epstein","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0315","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/pharmaceutics14030633","article-title":"Liposomal siRNA formulations for the treatment of herpes simplex virus-1: in vitro characterization of physicochemical properties and activity, and in vivo biodistribution and toxicity studies","volume":"14","author":"Jbara-Agbaria","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0320","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10616-009-9236-6","article-title":"Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas","volume":"61","author":"Xu","year":"2009","journal-title":"Cytotechnology"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0325","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/08982100902792855","article-title":"Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions: biological recognition and interactions of liposomes","volume":"19","author":"Szebeni","year":"2009","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0330","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2011.12.034","article-title":"Altering the immune response with lipid-based nanoparticles","volume":"161","author":"Landesman-Milo","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0335","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2010.03.020","article-title":"A new cell-based innate immune receptor assay for the examination of receptor activity, ligand specificity, signalling pathways and the detection of pyrogens","volume":"358","author":"Burger-Kentischer","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0340","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(20)31181-8","article-title":"Detection of sars-cov-2 in human breastmilk","volume":"395","author":"Gro\u00df","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0345","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in sars-cov-2 spike: evidence that d614g increases infectivity of the covid-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0350","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbrc.2020.11.026","article-title":"Functional importance of the d614g mutation in the sars-cov-2 spike protein","volume":"538","author":"Jackson","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0355","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-021-04352-y","article-title":"Evolution of enhanced innate immune evasion by sars-cov-2","volume":"602","author":"Thorne","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0360","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/2181254a0","article-title":"Immunogenicity of l 1210 murine leukaemia cells after treatment with neuraminidase","volume":"218","author":"Bagshawe","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0365","first-page":"205","article-title":"Antitumor effects induced by attenuated tumor cells. Part. V. Cytotoxic effects of incubation in acetate buffer on mh134 tumor cells","volume":"48","author":"Takakuwa","year":"1984","journal-title":"Agric. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0370","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of sars-cov-2 in hace2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0375","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00964-21","article-title":"The k18-human ace2 transgenic mouse model recapitulates non-severe and severe covid-19 in response to an infectious dose of the sars-cov-2 virus","volume":"96","author":"Dong","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0380","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57309","article-title":"Sars-cov-2 (covid-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0385","article-title":"Isolation and characterization of sars-cov-2 from the first us covid-19 patient","author":"Harcourt","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0390","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.chom.2020.11.003","article-title":"Integrative imaging reveals sars-cov-2-induced reshaping of subcellular morphologies","volume":"28","author":"Cortese","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0395","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.ATV.17.1.149","article-title":"Possible functional interactions of apolipoprotein b-100 segments that associate with cell proteoglycans and the apob\/e receptor","volume":"17","author":"Olsson","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0405","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.tips.2020.05.005","article-title":"In vitro and animal models for sars-cov-2 research","volume":"41","author":"Takayama","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.24171\/j.phrp.2020.11.1.02","article-title":"Identification of coronavirus isolated from a patient in Korea with covid-19","volume":"11","author":"Kim","year":"2020","journal-title":"Osong. Public Health Res. Perspect."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0415","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12250-020-00241-2","article-title":"Isolation and growth characteristics of sars-cov-2 in vero cell","volume":"35","author":"Yao","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0420","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0425","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type i and iii interferon responses in sars-cov-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.948770","article-title":"Toll-like receptor signaling in severe acute respiratory syndrome coronavirus 2-induced innate immune responses and the potential application value of toll-like receptor immunomodulators in patients with coronavirus disease 2019","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0435","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/s41467-021-23328-0","article-title":"Drug repurposing screens identify chemical entities for the development of covid-19 interventions","volume":"12","author":"Bakowski","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0440","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of sars-cov-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0445","article-title":"Host-directed therapies against early-lineage sars-cov-2 retain efficacy against b.1.1.7 variant","author":"Reuschl","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0450","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered tmprss2 usage by sars-cov-2 omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0455","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpb.2019.09.002","article-title":"Challenges and strategies in drug delivery systems for treatment of pulmonary infections","volume":"144","author":"Ho","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0460","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/tde-2017-0037","article-title":"Drug delivery to the lungs: challenges and opportunities","volume":"8","author":"Newman","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0465","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1128\/JVI.72.9.7221-7227.1998","article-title":"Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro","volume":"72","author":"Bourgeois","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0470","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1128\/AAC.00771-12","article-title":"Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide","volume":"56","author":"Donalisio","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0475","article-title":"Heparan sulfate proteoglycan-mediated internalization of extracellular vesicles ameliorates liver fibrosis by targeting hepatic stellate cells","volume":"1","author":"Li","year":"2022","journal-title":"Extracell. Ves."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0480","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","article-title":"Delivery strategies for sustained drug release in the lungs","volume":"75","author":"Loira-Pastoriza","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0485","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.actbio.2021.11.034","article-title":"Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants","volume":"140","author":"Liu","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2021.101497","article-title":"Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for sars-cov-2: a systematic review","volume":"70","author":"Kumar","year":"2021","journal-title":"Tissue Cell"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198943","article-title":"Evaluation of phenotypic and functional stability of raw 264.7 cell line through serial passages","volume":"13","author":"Taciak","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0500","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-020-03148-w","article-title":"Circuits between infected macrophages and t cells in sars-cov-2 pneumonia","volume":"590","author":"Grant","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0505","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives covid-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0510","doi-asserted-by":"crossref","first-page":"eabm9151","DOI":"10.1126\/scitranslmed.abm9151","article-title":"Sars-cov-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages","volume":"14","author":"Mart\u00ednez-Col\u00f3n","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0515","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41392-022-01106-8","article-title":"Alveolar macrophages: Achilles\u2019 heel of sars-cov-2 infection","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0520","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/icb.2008.101","article-title":"Tlr9 traffics through the golgi complex to localize to endolysosomes and respond to cpg DNA","volume":"87","author":"Chockalingam","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0525","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41419-021-03527-9","article-title":"Evidences for lipid involvement in sars-cov-2 cytopathogenesis","volume":"12","author":"Nardacci","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0530","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1038\/s41467-022-31097-7","article-title":"A global lipid map reveals host dependency factors conserved across sars-cov-2 variants","volume":"13","author":"Farley","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0535","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1039\/D0SC05064D","article-title":"Molecular mechanism of inhibiting the sars-cov-2 cell entry facilitator tmprss2 with camostat and nafamostat","volume":"12","author":"Hempel","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0540","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41589-022-01059-7","article-title":"Structure and activity of human tmprss2 protease implicated in sars-cov-2 activation","volume":"18","author":"Fraser","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0545","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/0092-8674(83)90291-X","article-title":"Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low ph compartment after internalization in coated vesicles","volume":"32","author":"Straubinger","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0550","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1002\/jps.21358","article-title":"Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development","volume":"97","author":"Drummond","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0555","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1021\/bi00472a025","article-title":"Endocytosis and intracellular fate of liposomes using pyranine as a probe","volume":"29","author":"Straubinger","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0560","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0565","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijpharm.2014.10.018","article-title":"Intranasal delivery of liposomal indole-3-carbinol improves its pulmonary bioavailability","volume":"477","author":"Song","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0570","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.3390\/ijms15045852","article-title":"Nanoparticle-mediated pulmonary drug delivery: a review","volume":"15","author":"Paranjpe","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0575","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2022.05.039","article-title":"Novel drug delivery systems and disease models for pulmonary fibrosis","volume":"348","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0580","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3109\/10717541003777225","article-title":"Biodistribution of antisense nanoparticles in mammary carcinoma rat model","volume":"17","author":"Elazar","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0585","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2015.11.056","article-title":"Effect of surface properties on liposomal siRNA delivery","volume":"79","author":"Xia","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0590","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0595","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2018.07.031","article-title":"Nanoparticle uptake by circulating leukocytes: a major barrier to tumor delivery","volume":"286","author":"Betker","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0600","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","article-title":"Liposome and immune system interplay: challenges and potentials","volume":"305","author":"Zahednezhad","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0605","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3390\/ijms23052666","article-title":"Kupffer cells and blood monocytes orchestrate the clearance of iron\u2013carbohydrate nanoparticles from serum","volume":"23","author":"Arsiwala","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0610","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07847","article-title":"Immune surveillance of the lung by migrating tissue monocytes","volume":"4","author":"Rodero","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0615","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3389\/fimmu.2019.00834","article-title":"Capturing the fantastic voyage of monocytes through time and space","volume":"10","author":"Teh","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0620","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2020.12.003","article-title":"Distinct developmental pathways from blood monocytes generate human lung macrophage diversity","volume":"54","author":"Evren","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0625","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000137805","article-title":"Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration","volume":"26","author":"Rosa","year":"1983","journal-title":"Pharmacology"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0630","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bbrc.2003.11.057","article-title":"Cationic liposome-mediated delivery of sirnas in adult mice","volume":"312","author":"Sioud","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0635","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4161\/cbt.5.12.3468","article-title":"Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer","volume":"5","author":"Landen","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2023.10.050_bb0640","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2010.08.030","article-title":"Route of administration-dependent anti-inflammatory effect of liposomal alendronate","volume":"148","author":"Haber","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.10.050_bb0645","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41423-020-00616-1","article-title":"SARS-COV-2 infection in k18-ace2 transgenic mice replicates human pulmonary disease in covid-19","volume":"18","author":"Arce","year":"2021","journal-title":"Cell. Mol. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:55:51Z","timestamp":1759164951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923007113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":120,"alternative-id":["S0168365923007113"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.050","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}